Pharmaceutical

Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and diabetes drugs.

May 8, 2025 - 06:00
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and diabetes drugs.
Read the original article

Tags:

Previous Article

FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy

Next Article

Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A deep dive on generative AI in health care, Pear sold for parts, and progress on stretchable skin

A deep dive on generative AI in health care, Pear sold ...

May 23, 2023

Which drugs are most likely to be approved in Lentiviru...

Mar 28, 2024

STAT+: Moving past regulatory obstacles, Protagonist Therapeutics looks to pivotal trial for its rare blood disorder therapy

STAT+: Moving past regulatory obstacles, Protagonist Th...

Jun 14, 2023